The impact of pharmacists' input on the screening, management and prevention of metabolic syndrome. [Protocol]

AL ADAWI, R., TONNA, A., STEWERT, D., RAYAN, C., ELEDRISI, M., and ABDELAZIZ, H.

2018

Citation

Rana Al Adawi, Antonella Tonna, Derek Stewert, Cristin Rayan, Mohsen Eledrisi, Hani Abdelaziz. The impact of pharmacists' input on the screening, management and prevention of metabolic syndrome. PROSPERO 2018 CRD42018089862 Available from:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018089862

Review question

To critically appraise, synthesise, and present the available evidence on the impact of pharmacists' input on the screening, prevention and management of metabolic syndrome (MetS).

Specific aims:
1- To determine the types of pharmacist interventions reported in the studies.
2- To describe the impact of the identified interventions as reported in the studies.
3- To identify the facilitators and barriers to the effective implementation of pharmacist interventions in the screening, prevention and management of MetS.
4- To characterise the populations who could benefit most from the interventions.

Searches

A thorough search and appraisal of the current published literature regarding the impact of pharmacists' interventions on the screening, prevention and management of MetS will be carried out.

An exploratory search has indicated that the first relevant article was published in 2008, and hence, all studies published from 2008 onwards in the English language will be included.

The search will be conducted electronically, using medical subject headings (MeSH), and will involve the following databases; MEDLINE, CINAHL, IPA and The Cochrane Library.

Additional search strategy information is available in the attached PDF document (link provided below).

Types of study to be included

All studies, irrespective of their design, will be included.

Condition or domain being studied

Metabolic syndrome screening, management and prevention, in which there is pharmacist involvement, and the impact of the pharmacists' input.

Participants/population

Inclusion criteria: all studies irrespective of the population groups involved will be included in the review.

Exclusion criteria: none.

Intervention(s), exposure(s)

Any intervention involving pharmacist input into the screening, prevention or management of MetS will be included.

Comparator(s)/control

Comparisons of the impact of the interventions with or without pharmacist input, if the data is available.

All studies will be included whether or not there is a control group.

Context
Pharmacists' input into the screening, management or prevention of metabolic syndrome, in diverse settings and involving a range of modalities.

Main outcome(s)

Assessment of the impact of pharmacists' input on the screening, management and prevention of metabolic syndrome.

The outcomes are likely to be diverse and may include the following: comparisons of different models of pharmacist input in MetS, descriptions of the process of development of the models, and the clinical and economic outcomes of such interventions.

Additional outcome(s)
None.

Data extraction (selection and coding)
Two reviewers will independently review the titles and abstracts of the studies identified in the searches, and the full texts of articles identified as being potentially eligible for inclusion will again be reviewed by two reviewers independently, and decisions made regarding inclusion/exclusion. Any disagreements over the eligibility of articles will be resolved by consultation with a third reviewer, and the included and excluded studies will be documented as per PRISMA guidelines.
Data will then be extracted from the studies selected for inclusion using a customised data extraction form which will be developed before the data extraction process begins. It is expected to include: study title, date, country, duration, population characteristics, mode of the interventions, study design, methodology, the primary and secondary outcomes, subgroup analysis and any other findings which address the study objectives.

Risk of bias (quality) assessment
The quality of the eligible studies will be critically appraised and assessed using standardised quality assessment tools appropriate for the type of study, as follows:

Randomised controlled trials: the Cochrane bias assessment tool.

Observational studies (case-control and cohort studies): the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) checklist.

Qualitative studies: the COREQ (COnsolidated criteria for REporting Qualitative research) bias assessment tool.

Bias will be assessed by two reviewers independently, with any disagreements be resolved by discussion with a third party.

Strategy for data synthesis
A descriptive synthesis of the results from the included studies will be undertaken, which will allow for an analysis of the evidence regarding the impact of pharmacist input into the screening, prevention and management of MetS, the available pharmacist models of care, and the clinical outcomes in relation to the MetS.

A narrative description and tabulation will be presented for each study, and comparisons and contrasts within and between studies in terms of populations, settings, methods, interventions, outcomes, subgroup analyses or post hoc analyses, facilitators and barriers will also be made.

Analysis of subgroups or subsets
Subgroup analyses will be carried out to explore the reported roles of pharmacists across different countries and geographical regions.

Data from qualitative and quantitative studies will be aggregated and described using a narrative approach.

Contact details for further information

Rana Moustafa Al Adawi

rahmed4@hamad.qa

Organisational affiliation of the review

Hamad Medical Corporation
Robert Gordon University

www.hamad.qa

www.RGU.ac.uk

Review team members and their organisational affiliations

Dr Rana Al Adawi. Hamad Medical Corporation
Dr Antonella Tonna. Robert Gordon University
Professor Derek Stewert. Robert Gordon University
Dr Cristin Rayan. Trinity College
Dr Mohsen Eledrisi. Hamad Medical Corporation
Dr Hani Abdelaziz. Hamad Medical Corporation

Type and method of review

Intervention, Prevention, Systematic review

Anticipated or actual start date

01 April 2018

Anticipated completion date

31 December 2018

Funding sources/sponsors

None

Conflicts of interest

None specified.
None known

Language

English

Country

Ireland, Qatar, Scotland

Stage of review

Review Ongoing

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

Community Pharmacy Services; Delivery of Health Care; Disease Management; Humans; Mass Screening; Metabolic Syndrome; Pharmaceutical Services; Pharmacies; Pharmacists; Primary Prevention; Professional Role

Date of registration in PROSPERO

07 March 2018

Date of first submission
04 March 2018

Stage of review at time of this submission
The review has not started

Stage	Started	Completed
Preliminary searches	No	No
Piloting of the study selection process	No	No
Formal screening of search results against eligibility criteria	No	No
Data extraction	No	No
Risk of bias (quality) assessment	No	No
Data analysis	No	No

The record owner confirms that the information they have supplied for this submission is accurate and complete and they understand that deliberate provision of inaccurate information or omission of data may be construed as scientific misconduct.

The record owner confirms that they will update the status of the review when it is completed and will add publication details in due course.

Versions
07 March 2018